Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | B7H3 CAR-T cells |
| Synonyms | |
| Therapy Description |
B7H3 CAR-T cells are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD276 (B7-H3) linked to a CD137 (4-1BB) co-stimulatory motif and a CD3zeta signaling domain, which potentially inhibit tumor growth (PMID: 30655315, J Clin Oncol 2025 43: 16_suppl, 2018). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| B7H3 CAR-T cells | CD276 Immune Cell Therapy 10 | B7H3 CAR-T cells are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD276 (B7-H3) linked to a CD137 (4-1BB) co-stimulatory motif and a CD3zeta signaling domain, which potentially inhibit tumor growth (PMID: 30655315, J Clin Oncol 2025 43: 16_suppl, 2018). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06500819 | Phase I | B7H3 CAR-T cells | Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors | Recruiting | USA | 0 |
| NCT06646627 | Phase I | B7H3 CAR-T cells | Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors | Recruiting | USA | 0 |